{
  "question_id": "fcmcq24070",
  "category": "fc",
  "educational_objective": "Immunize a patient aged 50 years or older against pneumococcus.",
  "metadata": {
    "care_types": [],
    "patient_types": [],
    "high_value_care": false,
    "question_updated": "12/26/2025"
  },
  "question_text": "A 72-year-old woman is evaluated during a wellness visit. Her vaccination history is as follows:Laboratory studies:VaccineTimingCOVID-19Up to date with vaccinations and boostersInfluenzaMost recent influenza seasonRecombinant zosterTwo doses 1 year agoTetanus, diphtheria, and acellular pertussis5 years ago; completed a primary series >20 years ago15-Valent pneumococcal conjugate1 year agoMedical conditions are hypertension and osteoporosis. Medications are amlodipine and alendronate.",
  "question_stem": "Which of the following vaccines should this patient receive now?",
  "options": [
    {
      "letter": "A",
      "text": "Recombinant herpes zoster vaccine",
      "peer_percentage": 0
    },
    {
      "letter": "B",
      "text": "Tetanus and diphtheria toxoids vaccine",
      "peer_percentage": 0
    },
    {
      "letter": "C",
      "text": "20-Valent pneumococcal conjugate vaccine",
      "peer_percentage": 0
    },
    {
      "letter": "D",
      "text": "23-Valent pneumococcal polysaccharide vaccine",
      "peer_percentage": 0
    },
    {
      "letter": "E",
      "text": "No vaccines are indicated",
      "peer_percentage": 0
    }
  ],
  "user_performance": {
    "user_answer": null,
    "correct_answer": "D",
    "result": null,
    "time_taken": null
  },
  "critique": "This patient should receive the 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Option D). Adults aged 50 years or older and adults 19 to 49 years with high-risk conditions (see Table: Indications for Pneumococcal Vaccination) should receive pneumococcal vaccination. Patients who have not previously received a pneumococcal vaccine can receive the 20-valent pneumococcal conjugate vaccine (PCV20), the 21-valent pneumococcal conjugate vaccine (PCV21), or the 15-valent pneumococcal conjugate vaccine (PCV15). For patients who received PCV15, such as this patient, PPSV23 should be administered at least 1 year later (a minimum interval of 8 weeks is recommended for patients with immunocompromise, cochlear implant, or cerebrospinal leak). This patient meets the age criteria for vaccination and should complete her pneumococcal immunization with PPSV23.Adults aged 50 years or older should receive the two-dose recombinant herpes zoster vaccine (Option A) administered 2 to 6 months apart. This patient has received both recommended herpes zoster vaccinations, and a third one is not indicated.The tetanus and diphtheria toxoids (Td) vaccine (Option B) is not indicated for this patient at this visit. After a primary vaccination series, patients should receive Td or the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine every 10 years. This patient received the Tdap vaccine 5 years ago and will not be due for a Td vaccination until age 77 years.Patients who receive PCV15 should subsequently receive PPSV23; these patients do not require additional vaccination with PCV20 (Option C) or PCV21.This patient is eligible for PPSV23. Therefore, advising that no vaccines are indicated (Option E) is inappropriate.",
  "key_points": [
    "Adults aged 50 years or older and adults aged 19 to 49 years with certain high-risk conditions should receive pneumococcal vaccination.",
    "Eligible adults who have not previously received a pneumococcal vaccination can receive the 20-valent pneumococcal conjugate vaccine, the 21-valent pneumococcal conjugate vaccine, or a combination of the 15-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine at least 1 year later (a minimum interval of 8 weeks is recommended for patients with immunocompromise, cochlear implant, or cerebrospinal fluid leak)."
  ],
  "references": "Centers for Disease Control and Prevention. Pneumococcal disease: summary of risk-based pneumococcal vaccination recommendations. Accessed October 31, 2024. www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/risk-indications.html#cdc_generic_section_5-risk-conditions",
  "related_content": {
    "syllabus": [
      "fcsec24008_24034"
    ],
    "learning_plan_topic": ""
  },
  "media": {
    "tables": [],
    "images": [],
    "svgs": [],
    "videos": []
  },
  "extracted_at": "2025-12-26T11:31:34.032143-06:00"
}